Navigation Links
NW Bio Responds To Shareholder Inquiries Following Immune Therapy Sector's Recent Market Decline
Date:12/16/2013

, CEO of NW Bio.  "Although there are never any guarantees of successful results in clinical trials, we hope to deliver strong results for both patients and investors through one or more of our multiple programs."  

About Northwest Biotherapeutics
Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.  NW Bio's proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company's lead product, DCVax-L, is currently in a 312-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer.  The Company's second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers.  The Company has also conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania.  The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.

Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, t
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Icahn Responds To Forest Labs Board
2. iMD Companies responds to shareholder questions
3. Concord Medical Responds to Unusual Market Activity in its Stock
4. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
5. Medbox Responds to Unprecedented Rise in Stock Price
6. TorkLaw Responds to FDA Warning Letter to St. Jude Medical Regarding Defective Heart Device; Now Representing Patients in 15 States
7. Star Scientific Responds to Plaintiffs Purported Class Action Lawsuit
8. Takeda Responds to Verdict in Diabetes Drug Case
9. National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill
10. Royalty Pharma Responds To Elans Tysabri Valuation
11. Inovio Pharmaceuticals Responds to Market Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 /CNW Telbec/ - ... Research-Based Pharmaceutical Companies (Rx&D), welcomes the 2015-2016 Quebec ... a working group on the biopharmaceutical industry. However, the ... budget. "We commend the government,s intent to ... announcement of measures to promote Quebec,s ...
(Date:3/27/2015)... Texas , March 27, 2015 The Temple ... in April to a 5,000-square-foot building at 1802 South First ... geographic area designated by the City of Temple ... Scott & White and the Central Texas Veterans Health Care ... and laboratory space to early stage biotechnology and life science ...
(Date:3/27/2015)... March 27, 2015 Zimmer Holdings, Inc. (NYSE and ... system for trauma patients. Available in both ... ® External Fixation System from Zimmer is a modular ...   The XtraFix System allows surgeons to ... external fixation process, resulting in saved time, costs and overall ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3
... SOMERSET, N.J., Jan. 30 Alfacell Corporation,(Nasdaq: ACEL ... occurred in the Phase IIIb clinical trial of its ... malignant,mesothelioma. Enrollment in the ONCONASE Phase IIIb clinical trial ... patients were enrolled in the,trial., In accordance with ...
... Breast ... Cancer Patients, EVERGREEN PARK, ... Centers in Evergreen Park, Illinois, near Chicago,( http://www.PursuingPainFreeCancer.org/breastcancer ), has announced ... for the,treatment of early stage breast cancer. The study involves the ...
Cached Medicine Technology:Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program 2Breast Cancer Treatment Is Reduced to One Week 2
(Date:3/27/2015)... While deep learning was the topic of many conversations ... the CEO of one start-up spoke passionately about using fast ... beyond the generally-agreed ceiling of 120 years. , Insilico Medicine, ... 12 companies recognized as the hottest GPU-powered startups in the ... Emerging Companies Summit have business models focused on self-driving ...
(Date:3/27/2015)... KING OF PRUSSIA, PA and LONDON, UK (PRWEB) March ... and current President of DrugDev SiteStart Melissa (Liss) Easy ... Under 40. , The 40 Under 40 list ... of age for their professional accomplishments and community involvement. ... and profiled in a special supplement of the Philadelphia ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and ... information on and analysis of the healthcare, regulatory and ... US in 2013 amounted to 316.1 million, having grown ... from 2008. The country’s increasingly elderly population and corresponding ... to boost the growth of the pharmaceutical market, which ...
(Date:3/27/2015)... SMI (Silicon Microstructures, Inc.), a global MEMS pressure ... MEMS based ultra-miniature pressure sensor designed especially for the ... 220um x 75um provides ample space for 1-French catheter ... industry leading in vivo drift performance of 2 ... pressure range from 0 to 1,100 mmHg absolute. ...
(Date:3/27/2015)... Bellevue, WA (PRWEB) March 27, 2015 ... it can be hard to know where to begin. ... an experienced Seattle trucking accident attorney, offers accident victims ... financial, and legal assistance to ensure their personal injury ... eBook begins by describing the first actions that should ...
Breaking Medicine News(10 mins):Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... , KENILWORTH, N.J., Aug. 11 ... an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus ... formulations of CLARINEX(R) (desloratadine). , , ... filed and consolidated since 2006 in the U.S. District Court ...
... , Survey seeks feedback from public to help ... CHICAGO, Aug. 11 Participate in the American Dental Association (ADA) ... and become eligible to win a $150 Amazon.com gift certificate and, at the ... ADA.org provides news and information on hundreds of dental topics, ranging from ...
... , MOUNTAIN VIEW, Calif., Aug. 11 VIVUS, ... and commercialization of novel therapeutic products, today reported its financial results for the ... Second Quarter Results , , Net loss ... as compared to net income of $3.6 million, or $0.06 per share, for ...
... , , VERNON HILLS, ... provider of vascular access management services, today announced the launch ... integrated network for physicians to act as one to deliver ... new program has the potential to ultimately save money for ...
... , , SAN BERNARDINO, Calif., Aug. 11 ... food junkies, the all new comic book superhero, Super Nutricia, created by Inland ... children. This is the first ever female superhero from IEHP,s squad of masked ... (Photo: http://www.newscom.com/cgi-bin/prnh/2 0 090811/DC6 0 ...
... newborns experiencing a fatal lack of oxygen, study finds , ... there,s been a nearly 40 percent drop in the risk ... infants in Scotland, new research has found. , The major ... of deaths caused by a lack of oxygen for the ...
Cached Medicine News:Health News:Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R) 2Health News:Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R) 3Health News:American Dental Association Web Survey Offers Chance at $150 Gift Certificate 2Health News:VIVUS Reports Second Quarter 2009 Financial Results 2Health News:VIVUS Reports Second Quarter 2009 Financial Results 3Health News:VIVUS Reports Second Quarter 2009 Financial Results 4Health News:VIVUS Reports Second Quarter 2009 Financial Results 5Health News:VIVUS Reports Second Quarter 2009 Financial Results 6Health News:VIVUS Reports Second Quarter 2009 Financial Results 7Health News:Lifeline Vascular Access Launches New Platform for Physicians to Share Best Practices and Improve Vascular Access Care 2Health News:Introducing All-New IEHP Superhero to Battle Childhood Obesity 2Health News:Introducing All-New IEHP Superhero to Battle Childhood Obesity 3Health News:Delivery-Related Infant Deaths Decline in Scotland 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: